GlassScriptPhysician profile
Zsamae C Lopez
NPI 1194186304
$2,913.37
in general payments reported to CMS, 2019-2025
29 companies · $608 in 2025
The $608 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,491 · 2022: $258 · 2023: $434 · 2024: $122 · 2025: $608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,032 · Education: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,032.06 |
| Education | $132.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $445.96 | 2021-2025 | Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $419.54 | 2021-2023 | Jardiance |
| Abbvie INC. | $299.28 | 2021 | |
| Mannkind Corporation | $249.96 | 2021-2023 | V-Go |
| Astrazeneca Pharmaceuticals LP | $191.79 | 2021-2025 | Enhertu |
| Lilly USA, LLC | $181.67 | 2021-2022 | |
| Amgen INC. | $138.92 | 2021-2023 | Evenity |
| Amarin Pharma, INC. | $132.00 | 2021-2022 | |
| Incyte Corporation | $114.42 | 2025 | Jakafi |
| Janssen Biotech, INC. | $92.24 | 2025 | Darzalex, Talvey, Erleada |
| Arbor Pharmaceuticals, INC. | $72.61 | 2021 | |
| Merck Sharp & Dohme LLC | $68.50 | 2025 | Keytruda, Keytruda Qlex, Welireg |
| Glaxosmithkline, LLC. | $65.74 | 2021-2025 | Ojjaara |
| Bayer Healthcare Pharmaceuticals INC. | $50.22 | 2025 | |
| Sanofi-Aventis U.S. LLC | $48.61 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $44.26 | 2025 | Tecentriq, Polivy |
| Janssen Pharmaceuticals, INC | $42.27 | 2022-2023 | Spravato, Invega Sustenna, Invega Trinza |
| Gilead Sciences, INC. | $41.75 | 2021 | |
| Novartis Pharmaceuticals Corporation | $36.16 | 2025 | |
| Almatica Pharma LLC | $27.17 | 2022 | |
| Adc Therapeutics America, INC. | $25.30 | 2025 | |
| Agios Pharmaceuticals, INC. | $18.85 | 2025 | Pyrukynd |
| Biohaven Pharmaceuticals, INC. | $18.16 | 2021 | |
| Taiho Oncology, INC. | $18.13 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.20 | 2022 | |
| Sunovion Pharmaceuticals INC. | $14.87 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $14.05 | 2025 | Libtayo |
| Alexion Pharmaceuticals, INC. | $12.81 | 2021 | |
| Dexcom, INC. | $11.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zsamae Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.